Sung Bae Lee

USPTO Granted Patents = 12 (Patent Applications = 7)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

7 out of 69

Lg Life Sciences, Limited

Agency for Defense Development

patents

Years Active: 2012-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12122766 - 3-azabicyclo[3,1,1]heptane derivative and pharmaceutical composition including same (2024-10-22),

2. 10927097 - Indole compound as inhibitor of necrosis (2021-02-23),

3. 9988379 - GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent (2018-06-05),

4. 9868731 - Indole amide compound as inhibitor of necrosis (2018-01-16),

5. 9540362 - Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent (2017-01-10),

6. 9000028 - Indole and indazole compounds as an inhibitor of cellular necrosis (2015-04-07),

7. 8889691 - Indole compounds as an inhibitor of cellular necrosis (2014-11-18),

8. 8887615 - Firearm having dual barrels (2014-11-18),

9. 8569307 - Indole compounds as an inhibitor of cellular necrosis (2013-10-29),

10. 8436038 - Indole and indazole compounds as an inhibitor of cellular necrosis (2013-05-07),

11. 8309586 - Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient (2012-11-13),

12. 8222414 - Indole compounds as an inhibitor of cellular necrosis (2012-07-17),

Title: Innovations of Sung Bae Lee

Introduction

Sung Bae Lee is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, holding a total of 12 patents. His work focuses on developing compounds that have therapeutic applications, particularly in the treatment of metabolic diseases.

Latest Patents

Among his latest patents is a compound known as 3-azabicyclo[3,1,1]heptane derivative, which is part of a pharmaceutical composition aimed at preventing or treating metabolic diseases such as diabetes and obesity. This compound exhibits ketohexokinase (KHK) inhibitory activity, making it a valuable asset in the fight against these conditions. Another notable patent involves an indole compound that serves as an inhibitor of necrosis. This compound is designed for the prevention and treatment of necrosis and associated diseases, showcasing Lee's commitment to advancing medical science.

Career Highlights

Sung Bae Lee has worked with notable companies in the pharmaceutical industry, including LG Life Sciences and LG Chem. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of medical treatments.

Collaborations

Lee has collaborated with esteemed colleagues such as Soon Ha Kim and Hyoung Jin Kim. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking inventions.

Conclusion

Sung Bae Lee's contributions to the field of pharmaceuticals through his innovative patents demonstrate his dedication to improving health outcomes. His work continues to influence the treatment of metabolic diseases, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.